Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage determinations for autologous platelet-rich plasma (PRP) used to treat wounds and other non-orthopedic conditions for Blue Cross Blue Shield - Rhode Island members, distinguishing Medicare Advantage and commercial product stances.
No material clinical or coverage changes in this revision.
Coverage Criteria
Payer-specific coverage statements
Coverage differs by product:
Coverage applies when using an FDA-cleared device as described in HCPCS G0465.
HCPCS G0460 is listed for non-diabetic chronic wounds and is not covered under this policy.
HCPCS G0465 is considered not medically necessary for commercial products; G0460 is not covered for non-diabetic chronic wounds/ulcers.
For commercial products, the use of platelet-rich plasma (autologous blood‑derived preparations) for the treatment of acute or chronic wounds — including surgical wounds and nonhealing ulcers — is not medically necessary. Additionally, HCPCS code G0460 (autologous platelet rich plasma for non‑diabetic chronic wounds/ulcers) is listed as not covered / not medically necessary for non‑diabetic chronic wounds/ulcers.
Coverage and payment are determined by the member's subscriber agreement or employer agreement, and those documents supersede this medical policy. Providers should verify member-specific benefits and eligibility by contacting the provider call center prior to rendering services.
The use of platelet‑rich plasma is considered not medically necessary for the treatment of acute or chronic wounds in commercial products. Examples include treatment of surgical wounds and nonhealing ulcers; the available evidence is insufficient to demonstrate clinically meaningful improvements in health outcomes for these indications.
Coding
| G0465 | Autologous platelet rich plasma (PRP) for diabetic chronic wounds/ulcers, using an FDA-cleared device (includes administration, dressings, phlebotomy, centrifugation, and all other preparatory procedures, per treatment) |
| G0460 | Autologous platelet rich plasma for non-diabetic chronic wounds/ulcers, including phlebotomy, centrifugation, and all other preparatory procedures, administration and dressings, per treatment |
Provider Actions & Billing Rules
Prior Authorization
Prior authorization is not applicable for this service.
- Prior authorization: Not applicable
Coding & Billing Rules
When billing for Medicare Advantage members, G0465 is covered only when filed with a covered (diabetic chronic wound/ulcer) diagnosis. G0460 is not covered for non‑diabetic chronic wounds/ulcers.
- G0465: Autologous platelet rich plasma for diabetic chronic wounds/ulcers — covered for Medicare Advantage when billed with a covered diagnosis
- G0460: Autologous platelet rich plasma for non‑diabetic chronic wounds/ulcers — not covered for Medicare Advantage; not medically necessary for Commercial Products
Verify Benefits & Eligibility
Providers must verify member-specific benefits and authorization requirements prior to providing services. Call the provider call center for eligibility and benefit details; benefits and eligibility are determined by the member's subscriber agreement or employer agreement and may vary among groups.
- Verify benefits/authorization: Call the provider call center for member-specific benefits and prior authorization information
- Benefits vary by group: Refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for coverage limitations
Commercial Noncoverage & Member Liability
For Commercial Products, platelet‑rich plasma (autologous blood‑derived preparations) is considered not medically necessary for treatment of acute or chronic wounds, including surgical wounds and nonhealing ulcers. Services determined to be not medically necessary or non‑covered may result in financial liability limits; providers may not bill members except as allowed by member agreements and informed written consent.
- Commercial noncoverage: PRP considered not medically necessary for acute or chronic wounds (including surgical wounds and nonhealing ulcers)
- Member financial liability: If service is not medically necessary or non‑covered, provider billing to member is subject to member agreement and prior informed written consent requirements
Background
Autologous platelet‑rich plasma (PRP) is prepared from the patient’s own blood by centrifugation to concentrate platelets suspended in plasma. When activated (for example with thrombin and calcium), platelets release multiple growth factors — including platelet‑derived growth factor (PDGF) and other mediators — that are proposed to promote tissue repair and wound healing. PRP preparations may be applied topically or as a gel dressing; while small trials and meta‑analyses have examined PRP for diabetic foot and other chronic wounds, the evidence is limited and results are inconsistent across wound types.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.